News

Zacks Investment Research on MSN3d
Arcturus Gets FDA's Fast Track Tag for Influenza Vaccine Candidate
Arcturus Therapeutics Holdings Inc. ARCT announced that the FDA has granted a Fast Track designation to its self-amplifying ...
Arcturus Therapeutics Receives U.S. FDA Fast Track Designation for the STARR® mRNA Vaccine Candidate ARCT-2304 for Pandemic Influenza A Virus H5N1
Arcturus Therapeutics Holdings Inc. (the "Company", "Arcturus", Nasdaq: ARCT), a commercial messenger RNA medicine company ...
Arcturus Therapeutics price target lowered to $45 from $71 at Guggenheim
Guggenheim analyst Seamus Fernandez lowered the firm’s price target on Arcturus Therapeutics (ARCT) to $45 from $71 and keeps a Buy rating on ...
Arcturus Gets FDA Fast-Track Designation for Pandemic Influenza A H5N1 Vaccine
Arcturus Therapeutics Holdings has won U.S. Food and Drug Administration fast-track designation for its ARCT-2304 pandemic flu vaccine candidate.
Arcturus Therapeutics granted fast track designation for ARCT-2304 from FDA
Arcturus Therapeutics (ARCT) announced that the FDA has granted fast track designation for the self-amplifying mRNA vaccine candidate, ...
High Growth Tech Stocks To Watch In The US April 2025
As the U.S. market navigates a turbulent landscape marked by volatile trading sessions and fluctuating economic indicators, investors are closely watching the impact of ongoing tariff developments and ...
ETF Daily News1mon
Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Given Consensus Recommendation of “Buy” by Analysts
Arcturus Therapeutics has a 12 month low of $12.75 and a 12 month high of $45.00. The stock’s 50-day moving average is $16.64 and its two-hundred day moving average is $18.32.
Mitsubishi UFJ Asset Management Co. Ltd. Purchases 4,647 Shares of Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT)
Mitsubishi UFJ Asset Management Co. Ltd. lifted its position in Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT – Free ...